{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:09:09Z","timestamp":1791544149907,"version":"4.3.4"},"reference-count":76,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtha.2025.06.025","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:21:11Z","timestamp":1751563271000},"page":"3033-3055","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3939-1403","authenticated-orcid":false,"given":"Tessa C.C.","family":"Jaspers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1549-5984","authenticated-orcid":false,"given":"P. Christian","family":"Remmelzwaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eefje P.S.","family":"Weersink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9447-0465","authenticated-orcid":false,"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakisa","family":"Khorsand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.06.025_bib1","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.06.025_bib2","series-title":"Prevention and management of venous thromboembolism","first-page":"122","year":"2010"},{"key":"10.1016\/j.jtha.2025.06.025_bib3","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.025_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jth.12070","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"11","author":"Farge","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.025_bib7","author":"InternistenVereniging"},{"key":"10.1016\/j.jtha.2025.06.025_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2141.2005.05953.x","article-title":"British Committee for Standards in Haematology. Guidelines on the use and monitoring of heparin","volume":"133","author":"Baglin","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.025_bib9","series-title":"Suggested dose adjustments of low molecular weight (LMW) heparins in adults with renal insufficiency","author":"Hull","year":"2022"},{"key":"10.1016\/j.jtha.2025.06.025_bib10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0049-3848(92)90213-T","article-title":"Correlation between anti-Xa and occurrence of thrombosis and haemorrhage in post-surgical patients treated with either logiparin (LMWH) or unfractionated heparin. Post-surgery Logiparin Study Group","volume":"65","author":"Bara","year":"1992","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.025_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239222","article-title":"Dosage reduction of low weight heparin in patients with renal dysfunction: effects on anti-Xa levels and clinical outcomes","volume":"15","author":"Hornung","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.06.025_bib12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1160\/TH07-02-0132","article-title":"Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry","volume":"98","author":"Falg\u00e1","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.025_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0140-6736(92)91054-C","article-title":"Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis","volume":"339","author":"Prandoni","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.06.025_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0049-3848(91)90403-J","article-title":"Laboratory monitoring of the clinical effects of low molecular weight heparins","volume":"14","author":"Walenga","year":"1991","journal-title":"Thromb Res Suppl"},{"key":"10.1016\/j.jtha.2025.06.025_bib15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1055\/s-0038-1642507","article-title":"Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group","volume":"71","author":"Alhenc-Gelas","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.025_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000477474","article-title":"Empirically reduced dosages of tinzaparin in patients with moderate-to-severe renal insufficiency lead to inadequate anti-Xa levels","volume":"137","author":"Olie","year":"2017","journal-title":"Nephron"},{"key":"10.1016\/j.jtha.2025.06.025_bib17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/ckj\/sft083","article-title":"Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series","volume":"6","author":"Russcher","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.jtha.2025.06.025_bib18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1592\/phco.2005.25.6.817","article-title":"Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls","volume":"25","author":"Shprecher","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2025.06.025_bib19","article-title":"Prevalentie van correcte anti Xa bloedspiegels bij pati\u00ebnten met verminderde nierfunctie op basis van dosisadvies conform richtlijn Nederlandse Federatie voor Nefrologie","volume":"1","author":"Smit","year":"2016","journal-title":"NPFO"},{"key":"10.1016\/j.jtha.2025.06.025_bib20","first-page":"360","article-title":"Dalteparin and anti-Xa: a complex interplay of therapeutic drug monitoring","volume":"77","author":"van Bergen","year":"2019","journal-title":"Neth J Med"},{"key":"10.1016\/j.jtha.2025.06.025_bib21","article-title":"Anti-Xa-activiteit van therapeutisch nadroparine bij verminderde nierfunctie en behandeling conform richtlijn Nederlandse federatie voor Nefrologie: vergelijking met standaarddosis bij normale nierfunctie","volume":"1","author":"van Ojik","year":"2016","journal-title":"NPFO"},{"key":"10.1016\/j.jtha.2025.06.025_bib24","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/17512433.2022.2132228","article-title":"Critical appraisal of evidence for anti-Xa monitoring and dosing of low-molecular-weight heparin in renal insufficiency","volume":"15","author":"van den Broek","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.025_bib29","author":"Pan Quimica Farmaceutica"},{"key":"10.1016\/j.jtha.2025.06.025_bib30","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00228-022-03344-9","article-title":"Therapeutically dosed low molecular weight heparins in renal impairment: a nationwide survey","volume":"78","author":"Jaspers","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.025_bib31","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2025.06.025_bib32","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1016\/j.jtha.2025.06.025_bib33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4082\/kjfm.23.0034","article-title":"RoBANS 2: a revised risk of bias assessment tool for nonrandomized studies of interventions","volume":"44","author":"Seo","year":"2023","journal-title":"Korean J Fam Med"},{"key":"10.1016\/j.jtha.2025.06.025_bib34","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2025.06.025_bib35","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/1060028020988362","article-title":"Cancer-associated venous thromboembolism treatment with anti-Xa versus weight-based enoxaparin: a retrospective evaluation of safety and efficacy","volume":"55","author":"Hart","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2025.06.025_bib36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/imj.13117","article-title":"Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital","volume":"46","author":"Petrie","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtha.2025.06.025_bib37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1078155217730129","article-title":"Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants","volume":"25","author":"Uppuluri","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jtha.2025.06.025_bib38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11239-024-03033-7","article-title":"Finding individualised treatment in obese needing enoxaparin (FIT ONE): a multicentre study of therapeutic enoxaparin and the role of anti-factor Xa monitoring","volume":"58","author":"Appay","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.06.025_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.thromres.2004.10.004","article-title":"Dosage of enoxaparin among obese and renal impairment patients","volume":"116","author":"Bazinet","year":"2005","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.025_bib40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/08971900211022300","article-title":"Evaluation of a treatment-dose enoxaparin protocol for patients with obesity","volume":"36","author":"Berger","year":"2023","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.jtha.2025.06.025_bib41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1590\/1806-9282.61.01.044","article-title":"Generic versus branded enoxaparin in prophylaxis and treatment of vein thrombosis","volume":"61","author":"Casella","year":"2015","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"10.1016\/j.jtha.2025.06.025_bib42","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1177\/0091270003253420","article-title":"Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin","volume":"43","author":"Chow","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.025_bib43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/1060028018821149","article-title":"Evaluation of treatment-dose enoxaparin in acutely ill morbidly obese patients at an academic medical center: a randomized clinical trial","volume":"53","author":"Curry","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2025.06.025_bib44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s11239-011-0584-7","article-title":"Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series","volume":"32","author":"Deal","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.06.025_bib45","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0038-1650553","article-title":"Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis","volume":"76","author":"Fiessinger","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.025_bib46","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s12094-019-02258-w","article-title":"Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin","volume":"22","author":"Galeano-Valle","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jtha.2025.06.025_bib47","first-page":"116","article-title":"Treatment of established venous thromboembolism with enoxaparin: preliminary report","volume":"556","author":"Huet","year":"1990","journal-title":"Acta Chir Scand Suppl"},{"key":"10.1016\/j.jtha.2025.06.025_bib48","first-page":"161","article-title":"An open trial of enoxaparin in the treatment of deep vein thrombosis of the leg","volume":"21","author":"Janvier","year":"1991","journal-title":"Haemostasis"},{"key":"10.1016\/j.jtha.2025.06.025_bib49","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1160\/TH05-01-0052","article-title":"Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients","volume":"93","author":"Kovacs","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.025_bib50","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1592\/phco.27.10.1347","article-title":"Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety","volume":"27","author":"Lachish","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2025.06.025_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40261-019-00855-9","article-title":"Stratifying therapeutic enoxaparin dose in morbidly obese patients by BMI class: a retrospective cohort study","volume":"40","author":"Lee","year":"2020","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jtha.2025.06.025_bib52","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11239-009-0320-8","article-title":"Enoxaparin dosing in the elderly using adjusted body weight","volume":"28","author":"Leri","year":"2009","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.06.025_bib53","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/0002512-200926010-00006","article-title":"Factors associated with bleeding in elderly hospitalized patients treated with enoxaparin sodium: a prospective, open-label, observational study","volume":"26","author":"Levin","year":"2009","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jtha.2025.06.025_bib54","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1345\/aph.1E096","article-title":"Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease","volume":"38","author":"Ma","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2025.06.025_bib55","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.thromres.2021.09.002","article-title":"Optimal enoxaparin dosing strategies for venous thromboembolism prophylaxis and treatment of high body weight patients","volume":"207","author":"Martin","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.025_bib56","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/01.CIR.0000136830.65073.C7","article-title":"Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin","volume":"110","author":"Montalescot","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2025.06.025_bib57","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2165\/00002018-200225100-00005","article-title":"Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients","volume":"25","author":"Pautas","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtha.2025.06.025_bib58","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.3324\/haematol.2008.002840","article-title":"Use of high intensity adjusted dose low molecular weight heparin in women with mechanical heart valves during pregnancy: a single-center experience","volume":"94","author":"Quinn","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.06.025_bib59","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1471-0528.2002.01525.x","article-title":"Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series","volume":"109","author":"Rodie","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2025.06.025_bib60","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.0004-8666.2003.00034.x","article-title":"Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring","volume":"43","author":"Rowan","year":"2003","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1016\/j.jtha.2025.06.025_bib61","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/j.1538-7836.2011.04458.x","article-title":"No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy","volume":"9","author":"Siguret","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.025_bib62","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1055\/s-0037-1614119","article-title":"Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU\/kg): anti-Xa and anti-IIa activities over 10 days","volume":"84","author":"Siguret","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.025_bib63","first-page":"63","article-title":"Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications","volume":"10","author":"Tahaineh","year":"2018","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.025_bib64","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/1076029614568713","article-title":"Evaluation and pharmacokinetics of treatment dose enoxaparin in hospitalized patients with morbid obesity","volume":"21","author":"Thompson-Moore","year":"2015","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jtha.2025.06.025_bib65","first-page":"42","article-title":"Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism","volume":"31","author":"Wilson","year":"2001","journal-title":"Haemostasis"},{"key":"10.1016\/j.jtha.2025.06.025_bib66","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/10600280231189488","article-title":"Risk stratification for supratherapeutic peak anti-Xa levels in adult patients on therapeutic enoxaparin","volume":"58","author":"Sheredy","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2025.06.025_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1377232","article-title":"How enoxaparin underdosing and sex contribute to achieving therapeutic anti-Xa levels","volume":"15","author":"Tinchon","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.025_bib68","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/jcph.2210","article-title":"Low early antifactor Xa target achievement rate of low-molecular-weight heparin for treating venous thromboembolism in patients in intensive care","volume":"63","author":"Zhang","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2025.06.025_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-020-02873-2","article-title":"A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin","volume":"112","author":"Aleidan","year":"2020","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2025.06.025_bib70","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ajog.2004.05.050","article-title":"A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation","volume":"191","author":"Barbour","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2025.06.025_bib71","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1046\/j.1471-0528.2003.02182.x","article-title":"Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy","volume":"110","author":"Jacobsen","year":"2003","journal-title":"BJOG"},{"key":"10.1016\/j.jtha.2025.06.025_bib72","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.ahj.2004.04.015","article-title":"Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment","volume":"148","author":"Kruse","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.jtha.2025.06.025_bib73","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1310\/hpj5203-214","article-title":"Clinical feasibility of monitoring enoxaparin anti-Xa concentrations: are we getting it right?","volume":"52","author":"Kufel","year":"2017","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.jtha.2025.06.025_bib74","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/00016340802449118","article-title":"Treatment of deep venous thrombosis in pregnant women","volume":"87","author":"Lykke","year":"2008","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jtha.2025.06.025_bib75","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0020-7292(00)00290-3","article-title":"Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin","volume":"71","author":"Rey","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jtha.2025.06.025_bib76","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0002-9378(03)00953-0","article-title":"Tinzaparin sodium for thrombosis treatment and prevention during pregnancy","volume":"190","author":"Smith","year":"2004","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jtha.2025.06.025_bib77","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imj.15010","article-title":"Tinzaparin for venous thromboembolism in patients with renal impairment: a single-centre, prospective pilot study","volume":"53","author":"Yeung","year":"2023","journal-title":"Intern Med J"},{"key":"10.1016\/j.jtha.2025.06.025_bib78","doi-asserted-by":"crossref","DOI":"10.24926\/iip.v14i1.5174","article-title":"Optimal dosing of enoxaparin in critically ill patients with venous thromboembolism","volume":"14","author":"Abdulla","year":"2023","journal-title":"Innov Pharm"},{"key":"10.1016\/j.jtha.2025.06.025_bib83","first-page":"609","article-title":"Enoxaparin dosing and antiXa monitoring in specialty populations: a case series of renal-impaired, extremes of body weight, pregnant, and pediatric patients","volume":"43","author":"Ahuja","year":"2018","journal-title":"P T"},{"key":"10.1016\/j.jtha.2025.06.025_bib84","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/1060028016656434","article-title":"Evaluation of enoxaparin dosing as a risk factor for bleeding in lung transplant recipients","volume":"50","author":"Sofjan","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jtha.2025.06.025_bib79","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0735-1097(97)00094-6","article-title":"Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A","volume":"29","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2025.06.025_bib80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.thromres.2024.02.007","article-title":"Smaller nadroparin dose reductions required for patients with renal impairment: a multicenter cohort study","volume":"236","author":"van Uden","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.025_bib81","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11239-019-01920-y","article-title":"Description of anti-Xa monitoring practices during low molecular weight heparin use","volume":"48","author":"Lin","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2025.06.025_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116835","article-title":"Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays","volume":"10","author":"Thomas","year":"2015","journal-title":"PLoS One"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:26:11Z","timestamp":1790817971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625004143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":76,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1538783625004143"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.025","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review on anti-Xa monitoring in the therapeutic use of low-molecular-weight heparins","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}